Nuvalent Inc. clinical trials
Acquired by GlaxoSmithKline, Jul 15, 2026 · source ↗
The registry lists 6 studies whose lead sponsor is Nuvalent Inc. 4 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 6, 2026.
- 6studies on the registry
- 4open to participants now
- 1phase 3 study under way
- 1reach primary completion within a year
Before and after it joined GlaxoSmithKline
- First submitted before Nuvalent Inc. became part of GlaxoSmithKline
- 6
- First submitted after Nuvalent Inc. became part of GlaxoSmithKline
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Coming up
1 of Nuvalent Inc.’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- DDec
- 1JJan ’27’27
- FFeb
- MMar
- AApr
- MMay
- JJun
- JJul
- AAug
- SSep
- OOct
- NNov
The study
Add it to your calendar (.ics) → With an account.
All 6 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
- Open now467%
- Status unknown or other233%
Over the years
- 222
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Nuvalent Inc.6 studies
Something wrong with this grouping? Tell us on the GlaxoSmithKline page.
Studies
Recruiting first, then most recently updated. Showing 6 of 6. All GlaxoSmithKline studies →
- A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)RecruitingNCT05384626Phase 1/2
Sponsor listed in the registry: Nuvalent Inc. · First submitted before Nuvalent Inc. became part of GlaxoSmithKline
- A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)RecruitingNCT06521554Phase 1
Sponsor listed in the registry: Nuvalent Inc. · First submitted before Nuvalent Inc. became part of GlaxoSmithKline
- Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLCRecruitingNCT06765109Phase 3
Sponsor listed in the registry: Nuvalent Inc. · First submitted before Nuvalent Inc. became part of GlaxoSmithKline
- A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)RecruitingNCT05118789Phase 1/2
Sponsor listed in the registry: Nuvalent Inc. · First submitted before Nuvalent Inc. became part of GlaxoSmithKline
- Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid TumorsAvailableNCT06834074
Sponsor listed in the registry: Nuvalent Inc. · First submitted before Nuvalent Inc. became part of GlaxoSmithKline
- Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid TumorsAvailableNCT06797362
Sponsor listed in the registry: Nuvalent Inc. · First submitted before Nuvalent Inc. became part of GlaxoSmithKline